PE20230385A1 - Anticuerpos anti-phf-tau y usos de estos - Google Patents
Anticuerpos anti-phf-tau y usos de estosInfo
- Publication number
- PE20230385A1 PE20230385A1 PE2022002218A PE2022002218A PE20230385A1 PE 20230385 A1 PE20230385 A1 PE 20230385A1 PE 2022002218 A PE2022002218 A PE 2022002218A PE 2022002218 A PE2022002218 A PE 2022002218A PE 20230385 A1 PE20230385 A1 PE 20230385A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- phf
- monoclonal antibody
- antigen binding
- binding fragment
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Abstract
Referido a un anticuerpo monoclonal aislado o fragmento de union al antigeno de este que comprende una region variable de cadena pesada que tiene una secuencia de polipeptidos seleccionada de las sec. con nums. de ident.: 71, 45, 51, 57, entre otros, o una region variable de cadena ligera que tiene una secuencia de polipeptidos seleccionada de las sec. con nums. de ident.: 72, 46, 52, 58, entre otros, en donde el anticuerpo monoclonal o fragmento de union al antigeno de este se une especificamente a un filamento helicoidal pareado (PHF)-tau, preferentemente pHF-tau humano. Tambien se refiere a un acido nucleico aislado que codifica el anticuerpo monoclonal o fragmento de union al antigeno. Ademas, se describen acidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, metodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatias.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007118P | 2020-04-08 | 2020-04-08 | |
| US202063026387P | 2020-05-18 | 2020-05-18 | |
| PCT/IB2021/052890 WO2021205359A1 (en) | 2020-04-08 | 2021-04-07 | Anti-phf-tau antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230385A1 true PE20230385A1 (es) | 2023-03-06 |
Family
ID=78023121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002218A PE20230385A1 (es) | 2020-04-08 | 2021-04-07 | Anticuerpos anti-phf-tau y usos de estos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230151083A1 (es) |
| EP (1) | EP4132569A4 (es) |
| JP (1) | JP2023521763A (es) |
| KR (1) | KR20220166308A (es) |
| CN (1) | CN115697393A (es) |
| AU (1) | AU2021251486A1 (es) |
| BR (1) | BR112022020410A2 (es) |
| CA (1) | CA3179914A1 (es) |
| CL (1) | CL2022002766A1 (es) |
| CO (1) | CO2022015737A2 (es) |
| CR (1) | CR20220505A (es) |
| DO (1) | DOP2022000218A (es) |
| EC (1) | ECSP22078815A (es) |
| IL (1) | IL297231A (es) |
| MX (1) | MX2022012628A (es) |
| PE (1) | PE20230385A1 (es) |
| PH (1) | PH12022553035A1 (es) |
| TW (1) | TW202204402A (es) |
| WO (1) | WO2021205359A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7362636B2 (ja) | 2018-03-05 | 2023-10-17 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｐｈｆ－タウ抗体及びその使用 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| JP2025512732A (ja) * | 2022-03-11 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 多重特異性抗体及びその使用 |
| KR20240156640A (ko) * | 2022-03-11 | 2024-10-30 | 얀센 파마슈티카 엔브이 | 다중특이적 항체 및 이의 용도 |
| WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6306513B2 (ja) * | 2011-12-20 | 2018-04-04 | ヤンセン バイオテツク，インコーポレーテツド | 抗ＰＨＦ−ｔａｕ抗体及びその使用 |
| WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| KR102742965B1 (ko) * | 2015-07-06 | 2024-12-13 | 유씨비 바이오파마 에스알엘 | 타우 결합 항체 |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| CN120329431A (zh) * | 2018-03-05 | 2025-07-18 | 詹森药业有限公司 | 检测神经退行性变的测定 |
| JP2023520811A (ja) * | 2020-04-08 | 2023-05-19 | アリアダ セラピューティクス，インコーポレイテッド | 抗ｃｄ９８抗体およびその使用 |
| MX2022012635A (es) * | 2020-04-08 | 2023-01-11 | Aliada Therapeutics Inc | Composiciones y métodos para distribución de barrera hematoencefálica. |
-
2021
- 2021-04-07 CN CN202180041278.1A patent/CN115697393A/zh active Pending
- 2021-04-07 JP JP2022561415A patent/JP2023521763A/ja active Pending
- 2021-04-07 AU AU2021251486A patent/AU2021251486A1/en not_active Abandoned
- 2021-04-07 PH PH1/2022/553035A patent/PH12022553035A1/en unknown
- 2021-04-07 PE PE2022002218A patent/PE20230385A1/es unknown
- 2021-04-07 KR KR1020227038806A patent/KR20220166308A/ko active Pending
- 2021-04-07 CR CR20220505A patent/CR20220505A/es unknown
- 2021-04-07 MX MX2022012628A patent/MX2022012628A/es unknown
- 2021-04-07 WO PCT/IB2021/052890 patent/WO2021205359A1/en not_active Ceased
- 2021-04-07 BR BR112022020410A patent/BR112022020410A2/pt unknown
- 2021-04-07 US US17/917,916 patent/US20230151083A1/en active Pending
- 2021-04-07 EP EP21783771.5A patent/EP4132569A4/en not_active Withdrawn
- 2021-04-07 CA CA3179914A patent/CA3179914A1/en active Pending
- 2021-04-07 IL IL297231A patent/IL297231A/en unknown
- 2021-04-08 TW TW110112656A patent/TW202204402A/zh unknown
-
2022
- 2022-10-06 CL CL2022002766A patent/CL2022002766A1/es unknown
- 2022-10-07 DO DO2022000218A patent/DOP2022000218A/es unknown
- 2022-10-07 EC ECSENADI202278815A patent/ECSP22078815A/es unknown
- 2022-10-31 CO CONC2022/0015737A patent/CO2022015737A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022020410A2 (pt) | 2023-01-03 |
| CN115697393A (zh) | 2023-02-03 |
| US20230151083A1 (en) | 2023-05-18 |
| IL297231A (en) | 2022-12-01 |
| CR20220505A (es) | 2023-05-31 |
| MX2022012628A (es) | 2023-01-11 |
| CA3179914A1 (en) | 2021-10-14 |
| WO2021205359A1 (en) | 2021-10-14 |
| KR20220166308A (ko) | 2022-12-16 |
| CO2022015737A2 (es) | 2023-02-27 |
| DOP2022000218A (es) | 2023-04-30 |
| ECSP22078815A (es) | 2022-11-30 |
| EP4132569A1 (en) | 2023-02-15 |
| AU2021251486A1 (en) | 2022-12-08 |
| CL2022002766A1 (es) | 2023-04-21 |
| PH12022553035A1 (en) | 2024-05-13 |
| JP2023521763A (ja) | 2023-05-25 |
| EP4132569A4 (en) | 2024-07-31 |
| TW202204402A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230385A1 (es) | Anticuerpos anti-phf-tau y usos de estos | |
| PE20231078A1 (es) | Anticuerpos anti-tigit | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| PE20091382A1 (es) | Anticuerpos que se une a il-4 y/o a il-13 | |
| AR080663A1 (es) | Proteinas de union especificas y sus usos | |
| EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| PE20190108A1 (es) | Moleculas de anticuerpo para el tratamiento del cancer | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| AR123628A1 (es) | Constructos anti-cd93 y usos de estos | |
| PE20020801A1 (es) | Anticuerpos contra el receptor del factor de crecimiento similar a insulina | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| PE20141787A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| AR128689A1 (es) | Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| AR130991A2 (es) | PROTEÍNAS DE UNIÓN A TGF-b-RII | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| UY39699A (es) | Anticuerpos anti-tau y usos de estos | |
| AR126464A1 (es) | Agentes para el tratamiento de cánceres positivos para cldn6 |